Your session is about to expire
← Back to Search
Cyclophosphamide for Pancreatic Cancer
Study Summary
This trial will be testing a combination of drugs and radiation to treat pancreatic cancer.
- Pancreatic Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Pembrolizumab is most often used for what type of patient?
"Pembrolizumab can be used to fight against three types of cancer: malignant melanoma of the skin, recurrent cervical cancer, and leukemia."
What is the maximum level of risk that patients face when taking Pembrolizumab?
"While there is some supportive data, pembrolizumab's safety falls in the middle of the spectrum with a score of 2."
Are there any spots left for people who want to enroll in this trial?
"From what is displayed on clinicaltrials.gov, it appears that this trial is no longer recruiting patients. Although this study is not currently looking for any new candidates, there are 2535 other trials that are."
Are there other similar drugs to Pembrolizumab that have been studied?
"Right now, 1813 clinical trials involving Pembrolizumab are active with 278 in Phase 3. Out of these studies, several are based in Philadelphia, Pennsylvania. But, in total, there are 63006 locations running trials for Pembrolizumab."
How many people have been allowed to participate in this research project?
"Although this specific trial is not recruiting at the moment, it was updated recently on June 3rd, 2022. There are currently 722 other trials actively recruiting patients with cancer of the pancreas and 1813 trials for Pembrolizumab."
Share this study with friends
Copy Link
Messenger